Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, non-randomized, open-label, phase II cohort study.

被引：0
|
作者：
Zhang, Nan
Li, Jiongyuan
Piao, Mingjian
Li, Chengjie
Xun, Ziyu
Zhang, Longhao
Wang, Yanyu
Liu, Kai
Wang, Shanshan
Wang, Hanping
Zhao, Hai-Tao
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China
[2] Peking Union Med Coll & Chinese Acad Med Sci, Div Pulm & Crit Care Med, State Key Lab Severe & Rare Dis, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16169
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of transhepatic artery chemoembolization (TACE) combined with tislelizumab (TIS) and lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma(uHCC)
    Nong, X.
    Xie, J-L.
    Zhang, Y-M.
    Liang, J-C.
    Pan, Z-L.
    Zhang, Z-M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S871 - S871
  • [2] Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial
    Nong, Xiang
    Zhang, Yu-Mei
    Liang, Jing-Chang
    Xie, Jin-Long
    Zhang, Zhi-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
    Lu, S.
    Zhang, W.
    Li, J.
    Hu, B.
    Li, X.
    Liu, Z.
    Wan, T.
    Tang, H.
    Liu, B.
    Cao, Y.
    Jiao, T.
    Zhang, Z.
    Wang, Y.
    Gao, B.
    Liu, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S594 - S595
  • [4] Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
    Zhang, Weihong
    Zhu, Bowen
    Tang, Yiyang
    Xue, Miao
    Wu, Yanqin
    Zhao, Yue
    Fan, Wenzhe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Jiang, Jiayun
    Zhang, Hui
    Lai, Jiejuan
    Zhang, Shiyu
    Ou, Yanjiao
    Fu, Yu
    Zhang, Leida
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1607 - 1622
  • [6] Donafenib combined with camrelizumab and transarterial chemoembolization (TACE) as conversion therapy for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm, phase II study.
    Cao, Yajuan
    Zhang, Xuebin
    Yue, Yang
    Peng, Jin
    Li, Binghua
    Shi, Jiong
    Tang, Min
    Chen, Chaobo
    Su, Ke
    Zhang, Laizhu
    Cheng, Chunxiao
    Yu, Decai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study
    Ding, Xiaoyan
    Sun, Wei
    Li, Wei
    Shen, Yanjun
    Guo, Xiaodi
    Teng, Ying
    Liu, Xiaomin
    Zheng, Linlin
    Li, Wendong
    Chen, Jinglong
    CANCER, 2021, 127 (20) : 3782 - 3793
  • [8] Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
    Shao, Guoliang
    Zeng, Hui
    Zhang, Zhewei
    Luo, Jun
    Zhang, Dinghu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 499 - 499
  • [9] Transarterial chemoembolization combined with donafenib or lenvatinib as first-line treatment for unresectable hepatocellular carcinoma: A single-center real-world retrospective study.
    Liu, Huan
    Huang, Mingsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
    Peng, Zhenwei
    Fan, Wenzhe
    Zhu, Bowen
    Wang, Guoying
    Sun, Junhui
    Xiao, Chengjiang
    Huang, Fuxi
    Tang, Rong
    Cheng, Yu
    Huang, Zhen
    Liang, Yuchuang
    Fan, Huishuang
    Qiao, Liangliang
    Li, Fuliang
    Zhuang, Wenquan
    Peng, Baogang
    Wang, Jiping
    Li, Jiaping
    Kuang, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (01) : 117 - +
12345